For research use only. Not for therapeutic Use.
Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.
| Catalog Number | I047329 |
| Purity | ≥95% |
| Reference | [1] Banerjee S, et al. Ann Oncol. 2018;29(4):917-923. |
